On Wednesday, July 17, Lindsay Winninger, the former head physical therapist for the US Ski Team on the women’s World Cup circuit and Olympic skier Lindsey Vonn’s private physical therapist, filed a federal antitrust lawsuit claiming Vail Health holds a monopoly in the regional physical therapy industry, reported the Aspen Times.
The lawsuit alleges that Vail Health controls 70% of the regional physical therapy market and that this gives the hospital “monopoly power to raise prices and exclude competition.”
The lawsuit further alleges that Vail Health collects “supra-competitive profits,” from its physical therapy business—20% to 40% above competitive market prices. That’s approximately US$140 per session for self-pay and more than US$300 per session under an insurance contract, as opposed to the more normal rate of US$65 to US$120 per session, according to the lawsuit.
The lawsuit claims that the Vail Health’s “exclusionary conduct” has forced 3 physical therapy providers to close their local offices in the last 2 years
Full Content: Aspen Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
NAR Seeks Dismissal of Pennsylvania Antitrust Lawsuit Filed by Broker
Dec 18, 2024 by
CPI
Vietnam Approves Sweeping Data Law Amid Industry Worries
Dec 18, 2024 by
CPI
Andrew Ferguson’s FTC Leadership Likely to Shape Big Tech and AI Regulation
Dec 18, 2024 by
CPI
Supreme Court to Review TikTok’s Legal Challenge Over US Ban
Dec 18, 2024 by
CPI
Prestigious Universities Accused of Price-Fixing in Financial Aid Scheme
Dec 18, 2024 by
CPI
Antitrust Mix by CPI
Remedies After Illumina/GRAIL– The Thorny Question of Proportionality
Dec 17, 2024 by
Aleksander Tombinski & Ciara Denihan
Why Was Illumina/GRAIL Blocked in the EU? Reviewing The European Commission’s Assessment of Vertical Mergers in Light of the 2022 Prohibition Decision
Dec 17, 2024 by
Will Sparks
The Role of Uncertainty in the Future European Horizontal Merger Guidelines: Lessons Learned From Illumina/GRAIL
Dec 17, 2024 by
Svend Albaek & Daniel Donath
Illumina’s Light on Article 22 EUMR: The Suspended Step and Uncertain Future of EU Merger Control Over Below-Threshold “Killer” Mergers
Dec 17, 2024 by
Anna Tzanaki
EU-Level Jurisdiction Over “Killer Acquisitions” in the Aftermath of Illumina/GRAIL
Dec 17, 2024 by
Peter Whelan